Відмінності між версіями «Le illness in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | These sufferers are | + | These sufferers are deemed to possess accomplished a minimal residual disease (MRD) unfavorable status.17-20 Quite a few phase II trials have demonstrated that patients attaining MRD negativity possess a signif-icantly longer survival than those who stay MRD optimistic, and this is correct for patients treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that sufferers obtaining MRD negativity had drastically longer progression-free and overall survivals, irrespectively from the remedy received.18 Unfortunately, even so, some of these studies had been flawed by inappropriate statistical evaluation, particularly the measurement of time-to-event outcomes from therapy initiation.27 Moreover, there are numerous caveats to the use of MRD evaluation in individuals with CLL.28 Very first, CLL remains incurable and at least 30 of individuals who obtain MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a disease relapse within 5 years.18 Secondly, in contrast to the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a [http://www.nanoplay.com/blog/40966/of-c1-n1-fragments-lastly-in-vivo-data-information/ Of C1/N1 fragments. Finally, in vivo {data|information] therapeutic benefit of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response when compared with remedy at the time of clinical relapse. That is an open-access paper. doi:10.3324/haematol.2013.099796 The on the web version of this short article features a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion have a larger probability of remaining MRD-positive following therapy in comparison with patients without having this chromosome abnormality.18 For all these factors, present guidelines for the management of sufferers with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this information in thoughts, we retrospectively evaluated the effect of MRD on the outcome of individuals with CLL getting any front-line therapy inside the context of an incredibly detailed prognostic evaluation, such as recently described recurrent gene mutations.survival and all round survival have been calculated making use of a landmark evaluation. All calculations have been performed using either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been deemed statistically substantial. Based on D ner's hierarchical model, 17/221 (eight ) and 40/221 (18 ) patients had 17p deletion and 11q deletion, respectively. TP53 mutations have been documented in 22/193 (11 ).Le illness in peripheral blood or bone marrow even when quite sensitive immunophenotypic or molecular solutions are applied to appear for residual illness. These patients are viewed as to possess achieved a minimal residual disease (MRD) negative status.17-20 Several phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than people that remain MRD optimistic, and that is correct for sufferers treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that patients getting MRD negativity had significantly longer progression-free and overall survivals, irrespectively from the therapy received.18 However, on the other hand, some of these studies had been flawed by inappropriate statistical evaluation, especially the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are several caveats to the use of MRD evaluation in individuals with CLL.28 Very first, CLL remains incurable and at least 30 of sufferers who reach MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually knowledge a illness relapse inside 5 years.18 Secondly, as opposed to the circumstance in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity after an initial MRD-negative response when compared with therapy in the time of clinical relapse. |
Версія за 00:51, 30 січня 2018
These sufferers are deemed to possess accomplished a minimal residual disease (MRD) unfavorable status.17-20 Quite a few phase II trials have demonstrated that patients attaining MRD negativity possess a signif-icantly longer survival than those who stay MRD optimistic, and this is correct for patients treated with traditional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that sufferers obtaining MRD negativity had drastically longer progression-free and overall survivals, irrespectively from the remedy received.18 Unfortunately, even so, some of these studies had been flawed by inappropriate statistical evaluation, particularly the measurement of time-to-event outcomes from therapy initiation.27 Moreover, there are numerous caveats to the use of MRD evaluation in individuals with CLL.28 Very first, CLL remains incurable and at least 30 of individuals who obtain MRD negativity immediately after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a disease relapse within 5 years.18 Secondly, in contrast to the predicament in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is no formal proof of a Of C1/N1 fragments. Finally, in vivo {data|information therapeutic benefit of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response when compared with remedy at the time of clinical relapse. That is an open-access paper. doi:10.3324/haematol.2013.099796 The on the web version of this short article features a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(five)R. Santacruz et al.deletion have a larger probability of remaining MRD-positive following therapy in comparison with patients without having this chromosome abnormality.18 For all these factors, present guidelines for the management of sufferers with CLL advise MRD assessment only inside clinical trials with "curative intention".36 With all this information in thoughts, we retrospectively evaluated the effect of MRD on the outcome of individuals with CLL getting any front-line therapy inside the context of an incredibly detailed prognostic evaluation, such as recently described recurrent gene mutations.survival and all round survival have been calculated making use of a landmark evaluation. All calculations have been performed using either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been deemed statistically substantial. Based on D ner's hierarchical model, 17/221 (eight ) and 40/221 (18 ) patients had 17p deletion and 11q deletion, respectively. TP53 mutations have been documented in 22/193 (11 ).Le illness in peripheral blood or bone marrow even when quite sensitive immunophenotypic or molecular solutions are applied to appear for residual illness. These patients are viewed as to possess achieved a minimal residual disease (MRD) negative status.17-20 Several phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than people that remain MRD optimistic, and that is correct for sufferers treated with standard chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Additionally, a phase III trial performed by the German CLL Study Group (GCLLSG) not too long ago revealed that patients getting MRD negativity had significantly longer progression-free and overall survivals, irrespectively from the therapy received.18 However, on the other hand, some of these studies had been flawed by inappropriate statistical evaluation, especially the measurement of time-to-event outcomes from treatment initiation.27 Moreover, there are several caveats to the use of MRD evaluation in individuals with CLL.28 Very first, CLL remains incurable and at least 30 of sufferers who reach MRD negativity just after front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC eventually knowledge a illness relapse inside 5 years.18 Secondly, as opposed to the circumstance in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there is certainly no formal proof of a therapeutic advantage of re-treatment upon documentation of MRD positivity after an initial MRD-negative response when compared with therapy in the time of clinical relapse.
